Organon Antidepressant Ariza Expected In 2002 When Remeron Generics Enter
Organon plans to continue its U.S. antidepressant franchise with the 5HT1A partial agonist Ariza.
You may also be interested in...
Pfizer expects an "approvable" action from FDA in September to set up a final round of negotiations over labeling for the antipsychotic Zeldox, Pfizer Global R&D President John Niblack indicated during a July 27 investor conference call.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials